Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines

J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):92-93. doi: 10.18176/jiaci.0667. Epub 2020 Jan 12.

Authors

M L Caballero¹, S Quirce¹

Affiliation

¹ Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.

PMID: 33433387
DOI: 10.18176/jiaci.0667

No abstract available

Keywords: Allergy; Anaphylaxis; COVID-19; Coronavirus; Excipient; Immediate drug hypersensitivity reaction; Pharmaceutical excipients; Vaccine.

MeSH terms

2019-nCoV Vaccine mRNA-1273
Anaphylaxis / chemically induced*
Anaphylaxis / immunology
BNT162 Vaccine
COVID-19 Vaccines / adverse effects*
COVID-19 Vaccines / chemistry
ChAdOx1 nCoV-19
Drug Compounding
Drug Hypersensitivity / etiology*
Drug Hypersensitivity / immunology
Excipients / adverse effects*
Humans
Risk Assessment
Risk Factors

Substances

2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine
COVID-19 Vaccines
ChAdOx1 nCoV-19
Excipients